Library

feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • Fluorescence  (1)
  • Key words Acute myeloid leukemia  (1)
  • 1
    ISSN: 1432-0584
    Keywords: Key words Acute myeloid leukemia ; Multidrug resistance ; P-glycoprotein ; Prognostic factors ; Flow cytometry
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract  Up till now, clinical data on the possible prognostic influence of multidrug resistance (MDR) in hematological malignancies have been inconsistent, probably due to technical pitfalls. Moreover, in most studies qualitative information on the presence/absence of MDR-1 expression has been used instead of quantitative results. In addition, results usually refer to the total BM population and not specifically to blast cells. In the present study we analyzed the expression of MDR-1 in a series of 50 newly diagnosed de novo AML using a double-staining technique: (a) monoclonal antibodies for the specific identification of blast cells and (b) the rhodamine-123 efflux assay, which allows a quantitative and calibrated measurement of MDR-1 function. Expression of MDR-1 was correlated with clinical, biological, and immunophenotypical disease characteristics. All patients were uniformly treated according to the AML 87/91 protocols of the Spanish Pethema Cooperative Group; the median age was 51±19 years and the FAB distribution was as follows: 2 M0, 9 M1, 9 M2, 12 M3, 11 M4, 5 M5, and 2 M6 cases. Upon grouping the 50 AML patients analyzed according to the level of rh123 elimination, it was observed that those cases with ≥30% decrease in rh123 fluorescence displayed higher WBC counts (9±12 vs 37±73×109/l, p=0.02) and platelet numbers (94±11 vs 35±25×109/l, p=0.02), together with a higher incidence of extramedullary involvement (35% vs 24%, p=0.02). Half of the patients (47%) displaying a low rh123 elimination (〈30%) showed M3 morphology, while among the 33 patients with a higher rate of rh123 elimination (≥30%), only four (12%) corresponded to the M3 morphological subtype (p=0.0006). From the immunophenotypic point of view, a low rate of rh123 elimination was associated with a lower expression of HLADR antigen (p=0.003) and a higher expression of CD117 (p=0.01). Regarding the possible prognostic influence of MDR1 expression, we found that a high rate of rh123 elimination (〉30%) was associated with a tendency towards poor disease outcome, illustrated by both a lower complete remission rate with the first cycle of chemotherapy (36% vs 56%) and a lower median disease-free survival (22 months vs median DFS not reached), although differences did not reach statistical significance (p=0.1 in both comparisons). This data shows that although MDR-1 can be a relevant parameter in the evaluation of AML patients, larger series of patients using appropiate techniques for specifically analyzing the MDR of blast cells will be necessary in order to establish the final clinical value of this parameter.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    ISSN: 1434-1948
    Keywords: Terpyridine ; Copper sensing ; Cyclam ; Fluorescence ; Solution studies ; Chemistry ; General Chemistry
    Source: Wiley InterScience Backfile Collection 1832-2000
    Topics: Chemistry and Pharmacology
    Notes: A synthetic strategy has been devised for the preparation of new compounds in which terpyridyl fragments are linked to 1,4,8,11-tetraazacyclotetradecane (cyclam). Reaction of excess cyclam with 4′-[(4-bromomethyl)phenyl]-2,2′:2″,6′-terpyridine afforded the ligand 1-[4′-p-tolyl-(2,2′:6′,2″-terpyridyl)]-1,4,8,11-tetraazacyclotetradecane (L1) in which the tetraaza macrocycle was covalently attached to one benzyl-terpyridyl fragment. Under similar conditions reaction of cyclam with excess 4′-[(4-bromomethyl)phenyl]-2,2′:2″,6′-terpyridine gave the tetra substituted cyclam derivative 1,4,8,11-[4′-p-tolyl-(2,2′:6′,2″-terpyridyl)]-1,4,8,11-tetraazacyclotetradecane (L2). The multidentate ligand L2 was crystallographically characterised by single-crystal X-ray diffraction techniques. Reaction of L1 with [Ru(mtpy)Cl3] gave the heteroleptic ruthenium(II) complex [Ru(L1)(mtpy)][PF6]2 (mtpy = 4′-methyl-2,2′:6′2″-terpyridine). The fluorescent intensity of the metallo-receptor [Ru(L1)(mtpy)][PF6]2 was quenched selectively in the presence of copper(II) in an aqueous environment. To gain insight into the nature of this interaction, potentiometric titrations on [Ru(L1)(mtpy)]2+ in the presence of Cu2+ were carried out. The quenching of the emission intensity was associated with the presence of the copper {Cu[Ru(L1)(mtpy)]}4+ complex in solution. The receptor 1-[4′-methyl-(2,2′:6′,2″-terpyridyl)]-1,4,8,11-tetraazacyclotetradecane (L3), in which the cyclam fragment is separated from the terpyriyl by a methylene group, has also been synthesised by reaction of 4′-bromomethyl-2,2′:2″,6′-terpyridine and cyclam. With L3 as starting material, the ruthenium complex [Ru(L3)(mtpy)]2+ was prepared in order to evaluate the effect that the nature of the spacer has on the quenching of the fluorescence upon addition of Cu2+.
    Additional Material: 5 Ill.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...